Abstract
Good news for the heart: The chronic use of rofecoxib causes adverse cardiovascular complications that prompted its withdrawal from the market. We recently modified rofecoxib into an NO-releasing, potent anti-inflammatory drug. Herein we describe the beneficial anti-hypertensive effects of the NO-releasing SO2NHOH COX-2 pharmacophore on blood pressure and its ability to enhance recovery in a cardiac ischemic reperfusion injury model.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
